Rescue Hearing

Rescue Hearing is a privately-held, preclinical-stage gene therapy company focused on hereditary hearing loss. RHI's initial product (RHI100) has generated positive proof-of-concept data and is advancing into the IND development stage. RHI100 targets a common form of hereditary deafness caused by mutations in the TMPRSS3 gene. TMPRSS3 mutations represent the most common form of hereditary deafness in the cochlear implant population. RHI also has two additional gene therapy assets in development.